• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·PFE
Held by 3 Gurus
Share

Pfizer Inc. Stocks

$ 24.29Last Updated 26.06.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

$ 138.41B

$ 24.29
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Manager
Fund
Portfolio Weight (%)
Change
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Sign up, to see portfolios that hold this stock
Sign up, to see portfolios that hold this stock

Latest news

23.06.2026 15:45

Morning in New York: Chipmakers Drag Stock Indices Lower

23.06.2026 08:00

Pfizer's lung cancer drug trial has failed. What will happen to the stock?

22.06.2026 15:15

Morning in New York: Geopolitics Favors Buyers

06.02.2026 15:00

Agomab Therapeutics IPO: Pfizer and Sanofi-backed biotech starts trading

04.02.2026 15:45

Morning in New York: investors in search of a foothold

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Pfizer Inc. operates as a global biopharmaceutical enterprise, actively involved in the discovery, innovation, manufacturing, promotion, distribution, and sale of its pharmaceutical portfolio across the United States, Europe, and numerous international markets. The company’s comprehensive product range encompasses medicines and vaccines for a wide spectrum of therapeutic areas. These include treatments for cardiovascular and metabolic conditions, migraines, and women's health, exemplified by brands such as Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family. Pfizer also addresses infectious diseases with products like the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba, alongside its contributions to COVID-19 prevention and treatment, featuring Comirnaty and Paxlovid, and ongoing efforts in mRNA and antiviral technologies. Further offerings include biosimilars for chronic immune and inflammatory disorders, represented by Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo; and specialized medications for conditions such as amyloidosis, hemophilia, endocrine diseases, and sickle cell disease, found under brands like the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin. The company also supplies sterile injectable and anti-infective medications, including Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga, in addition to a substantial oncology and specialty pipeline featuring biologics, small molecules, immunotherapies, and biosimilars like Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi. Additionally, Pfizer engages in contract manufacturing services. Its clientele is diverse, spanning wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical offices, and integrated healthcare delivery systems. The company maintains significant collaboration agreements with partners such as Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE. Pfizer Inc. was established in 1849 and has its corporate headquarters situated in New York, New York.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA, reasonably priced

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of PFE is 29 and suggests 17.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.06.2026 15:01

Collective Sentiment: How Much Influence Do Financial Influencers Have?

28.06.2026 11:41

The U.S. and Iran continued to exchange blows despite the agreement

27.06.2026 16:01

Small caps last week: Hertz's dark day, Wendy’s meme rally, OpenAI IPO beneficiaries

27.06.2026 13:01

Fantastic mega-adventures, magical healings, and amazing transformations

27.06.2026 09:42

SpaceX will be added to the Nasdaq 100 index as early as July. What does this mean for investors?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026